Visceral Pain Market, By Therapeutics (Analgesics, Pain Modifiers, and others), Indication (Interstitial Cystitis, Crohns, Irritable Bowel, and Chronic Prostatitis) and by Region (NA, EU, APAC, LA, MEA) Analysis, Size, Share, Trends, & Forecast from 2021-2027
REPORT HIGHLIGHT
The Visceral Pain Market is expected to be valued at USD 11,700.1 million in 2020, growing with 3.9% CAGR during the forecast period, 2021-2027.
Internal pain characterized by a persistent, intense, and squeezing aching throughout the body is known as visceral pain. Medical disorders such as infection, trauma, and chronic illness commonly cause inflammation in the abdominal area, which includes the uterus, stomach, rectum, and bladder. This can cause discomfort that lasts for days, weeks, or months as if something is squeezing out of the body.
Market Dynamics
The visceral pain market is expected to be driven by pharmaceutical companies' increasing focus on research and development, as well as government initiatives, throughout the forecast period. The market is anticipated to develop considerably during the forecast period as a result of greater collaboration among pharmaceutical companies.
The surge in interest among scientists and researchers in researching pain originating from internal organs has corresponded with a growing understanding of the importance of visceral pain in patients. Various types of medicines on the market have been used off-label for pain management in recent years, despite their analgesic properties. The global market for novel targeted pharmaceutical therapy will continue to grow as a result of this factor. The worldwide geriatric population is anticipated to reach 2 billion by 2050, contributing significantly to the market's global growth.
Therapeutics Takeaway
Analgesics accounted for the greatest proportion of the worldwide visceral pain market in 2019, and this dominance is anticipated to continue throughout the research period. The segment's growth is projected to be fueled by widely available goods paired with over-the-counter sales in the future years. Analgesics include narcotics and nonsteroidal anti-inflammatory medications (NSAIDs).
Indication Takeaway
Irritable bowel syndrome is expected to be the fastest-growing category. The prevalence of this illness has grown as a result of changing dietary choices and lifestyles, which is likely to boost demand for disease-management treatments. Because there are few therapeutic alternatives for visceral discomfort, numerous firms have opted to engage in research and development.
Regional Takeaway
North America led the worldwide visceral pain market in 2019, owing to the expanding cancer patient pool. This trend is anticipated to continue over the forecast period. One of the most dreaded and incapacitating symptoms of cancer is pain. Patients with cancer endure agony not just throughout the diagnosis process, but even after therapy has ended.
Key Vendor Takeaway
Some of the major players in this industry include Pfizer Inc, Zyla Life Sciences, Takeda Pharmaceutical Company Limited, Sanofi, Novartis AG, Mallinckrodt Pharmaceuticals, Johnson & Johnson Services Inc, Horizon Therapeutics plc, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Bayer AG, AstraZeneca, Astellas Pharma Inc., Allergan Inc, Addex Therapeutics, and Abbvie.
The market size and forecast for each segment and sub-segments has been considered as below:
- Historical Year – 2016 to 2019
- Base Year – 2020
- Projected Year – 2021 to 2027
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL VISCERAL PAIN MARKET KEY PLAYERS
- Zyla Life Sciences
- Takeda Pharmaceutical Company Limited
- Sanofi
- Pfizer Inc
- Novartis AG
- Mallinckrodt Pharmaceuticals
- Johnson & Johnson Services Inc
- Horizon Therapeutics plc
- GlaxoSmithKline plc
- Boehringer Ingelheim International GmbH
- Bayer AG
- AstraZeneca
- Astellas Pharma Inc.
- Allergan Inc
- Addex Therapeutics
- Abbvie
GLOBAL VISCERAL PAIN MARKET, BY THERAPEUTICS
- Analgesics
- Pain Modifiers
- Others
GLOBAL VISCERAL PAIN MARKET, BY INDICATION
- Interstitial Cystitis
- Crohn’s
- Irritable Bowel
- Chronic Prostatitis
GLOBAL VISCERAL PAIN MARKET, BY REGION
- North America
- The U.S.
- Canada
- Europe
- Germany
- France
- Italy
- Spain
- United Kingdom
- Rest of Europe
- Asia Pacific
- India
- China
- South Korea
- Japan
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Rest of MEA
TABLE OF CONTENT
1. VISCERAL PAIN MARKET OVERVIEW
1.1. Study Scope
2. EXECUTIVE SUMMARY
2.1. Market Snippet
2.1.1. Market Snippet by Therapeutics
2.1.2. Market Snippet by Indication
2.1.3. Market Snippet by Region
2.2. Competitive Insights
3. VISCERAL PAIN KEY MARKET TRENDS
3.1. Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Market Opportunities
3.4. Market Future Trends
4. VISCERAL PAIN INDUSTRY STUDY
4.1. Porter’s Five Forces Analysis
4.2. Marketing Strategy Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. VISCERAL PAIN MARKET: COVID-19 IMPACT ANALYSIS
5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
5.2.1. Top Performing Segments
5.2.2. Marginal Growth Segments
5.2.3. Top Looser Segments
5.2.4. Marginal Loss Segments
6. VISCERAL PAIN MARKET LANDSCAPE
6.1. Market Share Analysis, 2019
6.2. Key Innovators Analysis
6.3. Breakdown Data, by Key Manufacturer
6.3.1. Established Players’ Analysis
6.3.2. Emerging Players’ Analysis
7. VISCERAL PAIN MARKET – BY THERAPEUTICS
7.1. Overview
7.1.1. Segment Share Analysis, By Therapeutics, 2020 & 2027 (%)
7.2. Analgesics
7.2.1. Overview
7.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Billion)
7.3. Pain Modifiers
7.3.1. Overview
7.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Billion)
7.4. Others
7.4.1. Overview
7.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Billion)
8. VISCERAL PAIN MARKET – BY INDICATIONS
8.1. Overview
8.1.1. Segment Share Analysis, By Indications, 2020 & 2027 (%)
8.2. Interstitial Cystitis
8.2.1. Overview
8.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Billion)
8.3. Crohn’s
8.3.1. Overview
8.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Billion)
8.4. Irritable Bowel
8.4.1. Overview
8.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Billion)
8.5. Chronic Prostatitis
8.5.1. Overview
8.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Billion)
9. VISCERAL PAIN MARKET– BY GEOGRAPHY
9.1. Introduction
9.1.1. Segment Share Analysis, By Geography, 2020 & 2027 (%)
9.2. North America
9.2.1. Overview
9.2.2. Key Manufacturers in North America
9.2.3. North America Market Size and Forecast, By Country, 2016 - 2027 (US$ Billion)
9.2.4. North America Market Size and Forecast, By Therapeutics, 2016 - 2027 (US$ Billion)
9.2.5. North America Market Size and Forecast, By Indication, 2016 - 2027 (US Billion)
9.2.6. U.S.
9.2.6.1. Overview
9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Billion)
9.2.6.3. U.S. Market Size and Forecast, By Therapeutics, 2016 - 2027 (US$ Billion)
9.2.6.4. U.S. Market Size and Forecast, By Indication, 2016 - 2027 (US Billion)
9.2.7. Canada
9.2.7.1. Overview
9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Billion)
9.2.7.3. Canada Market Size and Forecast, By Therapeutics, 2016 - 2027 (US$ Billion)
9.2.7.4. Canada Market Size and Forecast, By Indication, 2016 - 2027 (US Billion)
9.3. Europe
9.3.1. Overview
9.3.2. Key Manufacturers in Europe
9.3.3. Europe Market Size and Forecast, By Country, 2016 - 2027 (US$ Billion)
9.3.4. Europe Market Size and Forecast, By Therapeutics, 2016 - 2027 (US$ Billion)
9.3.5. Europe Market Size and Forecast, By Indication, 2016 - 2027 (US Billion)
9.3.6. Germany
9.3.6.1. Overview
9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Billion)
9.3.6.3. Germany Market Size and Forecast, By Therapeutics, 2016 - 2027 (US$ Billion)
9.3.6.4. Germany Market Size and Forecast, By Indication, 2016 - 2027 (US Billion)
9.3.7. Italy
9.3.7.1. Overview
9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Billion)
9.3.7.3. Italy Market Size and Forecast, By Therapeutics, 2016 - 2027 (US$ Billion)
9.3.7.4. Italy Market Size and Forecast, By Indication, 2016 - 2027 (US Billion)
9.3.8. United Kingdom
9.3.8.1. Overview
9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Billion)
9.3.8.3. United Kingdom Market Size and Forecast, By Therapeutics, 2016 - 2027 (US$ Billion)
9.3.8.4. United Kingdom Market Size and Forecast, By Indication, 2016 - 2027 (US Billion)
9.3.9. France
9.3.9.1. Overview
9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Billion)
9.3.9.3. France Market Size and Forecast, By Therapeutics, 2016 - 2027 (US$ Billion)
9.3.9.4. France Market Size and Forecast, By Indication, 2016 - 2027 (US Billion)
9.3.10. Rest of Europe
9.3.10.1. Overview
9.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Billion)
9.3.10.3. Rest of Europe Market Size and Forecast, By Therapeutics, 2016 - 2027 (US$ Billion)
9.3.10.4. Rest of Europe Market Size and Forecast, By Indication, 2016 - 2027 (US Billion)
9.4. Asia Pacific
9.4.1. Overview
9.4.2. Key Manufacturers in Asia Pacific
9.4.3. Asia Pacific Market Size and Forecast, By Country, 2016 - 2027 (US$ Billion)
9.4.4. Asia Pacific Market Size and Forecast, By Therapeutics, 2016 - 2027 (US$ Billion)
9.4.5. Asia Pacific Market Size and Forecast, By Indication, 2016 - 2027 (US Billion)
9.4.6. India
9.4.6.1. Overview
9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Billion)
9.4.6.3. India Market Size and Forecast, By Therapeutics, 2016 - 2027 (US$ Billion)
9.4.6.4. India Market Size and Forecast, By Indication, 2016 - 2027 (US Billion)
9.4.7. China
9.4.7.1. Overview
9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Billion)
9.4.7.3. China Market Size and Forecast, By Therapeutics, 2016 - 2027 (US$ Billion)
9.4.7.4. China Market Size and Forecast, By Indication, 2016 - 2027 (US Billion)
9.4.8. Japan
9.4.8.1. Overview
9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Billion)
9.4.8.3. Japan Market Size and Forecast, By Therapeutics, 2016 - 2027 (US$ Billion)
9.4.8.4. Japan Market Size and Forecast, By Indication, 2016 - 2027 (US Billion)
9.4.9. Rest of APAC
9.4.9.1. Overview
9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Billion)
9.4.9.3. Rest of APAC Market Size and Forecast, By Therapeutics, 2016 - 2027 (US$ Billion)
9.4.9.4. Rest of APAC Market Size and Forecast, By Indication, 2016 - 2027 (US Billion)
9.5. Latin America
9.5.1. Overview
9.5.2. Key Manufacturers in Latin America
9.5.3. Latin America Market Size and Forecast, By Country, 2016 - 2027 (US$ Billion)
9.5.4. Latin America Market Size and Forecast, By Therapeutics, 2016 - 2027 (US$ Billion)
9.5.5. Latin America Market Size and Forecast, By Indication, 2016 - 2027 (US Billion)
9.5.6. Brazil
9.5.6.1. Overview
9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Billion)
9.5.6.3. Brazil Market Size and Forecast, By Therapeutics, 2016 - 2027 (US$ Billion)
9.5.6.4. Brazil Market Size and Forecast, By Indication, 2016 - 2027 (US Billion)
9.5.7. Mexico
9.5.7.1. Overview
9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Billion)
9.5.7.3. Mexico Market Size and Forecast, By Therapeutics, 2016 - 2027 (US$ Billion)
9.5.7.4. Mexico Market Size and Forecast, By Indication, 2016 - 2027 (US Billion)
9.5.8. Argentina
9.5.8.1. Overview
9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Billion)
9.5.8.3. Argentina Market Size and Forecast, By Therapeutics, 2016 - 2027 (US$ Billion)
9.5.8.4. Argentina Market Size and Forecast, By Indication, 2016 - 2027 (US Billion)
9.5.9. Rest of Europe
9.5.9.1. Overview
9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Billion)
9.5.9.3. Rest of LATAM Market Size and Forecast, By Therapeutics, 2016 - 2027 (US$ Billion)
9.5.9.4. Rest of LATAM Market Size and Forecast, By Indication, 2016 - 2027 (US Billion)
9.6. Middle East and Africa
9.6.1. Overview
9.6.2. Key Manufacturers in Middle East and Africa
9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2016 - 2027 (US$ Billion)
9.6.4. Middle East and Africa Market Size and Forecast, By Therapeutics, 2016 - 2027 (US$ Billion)
9.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2016 - 2027 (US$ Billion)
9.6.6. Saudi Arabia
9.6.6.1. Overview
9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Billion)
9.6.6.3. Saudi Arabia Market Size and Forecast, By Therapeutics, 2016 - 2027 (US$ Billion)
9.6.6.4. Saudi Arabia Market Size and Forecast, By Indication, 2016 - 2027 (US$ Billion)
9.6.7. United Arab Emirates
9.6.7.1. Overview
9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Billion)
9.6.7.3. United Arab Emirates Market Size and Forecast, By Therapeutics, 2016 - 2027 (US$ Billion)
9.6.7.4. United Arab Emirates Market Size and Forecast, By Indication, 2016 - 2027 (US$ Billion)
9.6.8. Rest of MEA
9.6.8.1. Overview
9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Billion)
9.6.8.3. Rest of MEA Market Size and Forecast, By Therapeutics, 2016 - 2027 (US$ Billion)
9.6.8.4. Rest of MEA Market Size and Forecast, By Indication, 2016 - 2027 (US$ Billion)
10. KEY VENDOR ANALYSIS
10.1. Competitive Dashboard
10.2. Company Profiles
10.2.1. Zyla Life Sciences
10.2.1.1. Company Snapshot
10.2.1.2. Financial Performance
10.2.1.3. Product Benchmarking
10.2.1.4. Strategic Initiatives
10.2.2. Takeda Pharmaceutical Company Limited
10.2.3. Sanofi
10.2.4. Pfizer Inc
10.2.5. Novartis AG
10.2.6. Mallinckrodt Pharmaceuticals
10.2.7. Johnson & Johnson Services Inc
10.2.8. Horizon Therapeutics plc
10.2.9. GlaxoSmithKline plc
10.2.10. Boehringer Ingelheim International GmbH
10.2.11. Bayer AG
10.2.12. AstraZeneca
10.2.13. Astellas Pharma Inc.
10.2.14. Allergan Inc
10.2.15. Addex Therapeutics
10.2.16. Abbvie
11. 360 DEGREE ANALYST VIEW
12. APPENDIX
12.1. Research Methodology
12.2. References
12.3. Abbreviations
12.4. Disclaimer
12.5. Contact Us
